Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders?

Biometals. 2017 Feb;30(1):1-16. doi: 10.1007/s10534-016-9981-x. Epub 2016 Nov 16.

Abstract

The prevalence of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and Huntington's disease are increased by age. Alleviation of their symptoms and protection of normal neurons against degeneration are the main aspects of the research to establish novel therapeutic strategies. Iron as the one of most important cation not only play important role in the structure of electron transport chain proteins but also has pivotal duties in cellular activities. But disruption in iron hemostasis can make it toxin to neurons which causes lipid peroxidation, DNA damage and etc. In patients with Alzheimer and Parkinson misbalancing in iron homeostasis accelerate neurodegeneration and cause neuroinflmmation. mTOR as the common signaling pathway between cancer and neurodegenerative disorders controls iron uptake and it is in active form in both diseases. Anti-cancer drugs which target mTOR causes iron deficiency and dual effects of mTOR inhibitors can candidate them as a therapeutic strategy to alleviate neurodegeneration/inflammation because of iron overloading.

Keywords: Alzheimer’s disease; Cancer; Iron; Neuroinflammation; Parkinson’s disease; mTOR.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology
  • Humans
  • Huntington Disease / drug therapy*
  • Huntington Disease / metabolism
  • Huntington Disease / pathology
  • Iron / metabolism*
  • Lipid Peroxidation / drug effects
  • Neoplasms / drug therapy
  • Nerve Degeneration / drug therapy
  • Nerve Degeneration / metabolism
  • Nerve Degeneration / pathology
  • Neurons / drug effects
  • Neurons / pathology
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology
  • Signal Transduction / drug effects
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / genetics*

Substances

  • Iron
  • MTOR protein, human
  • TOR Serine-Threonine Kinases